Read the patient blogs and hear what is most relevant to myeloma patients.
Replay the #IMFASH23 Support Group Leader Discussion from ASH 2023
Each year, the IMF brings support group leaders from across the U.S. to the annual American Society of Hematology Meeting and Expo. Listen to a discussion hosted by IMF Chief Medical Officer, Dr. Joseph Mikhael.
Previous Post
Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for ASCT: Primary Results of the Perseus Trial
Next Post
Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Long Term Follow up Results of the Randomized GMMG Phase III Multicenter Trial Relapse




